Metabolism-directed optimisation of antithrombotics: The Prodrug principle

Current Pharmaceutical Design

Volumn 12, Issue 1, 2006, Pages 73-91

  Peterlin Masic L ^a   Cesar, J ^a   Zega, Anamarija ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Antithrombotic; Factor VIIa; Factor Xa; Platelet; Prodrug; Thrombin

Indexed keywords

1,2,4 OXADIAZOLIN 5 ONE DERIVATIVE; 3 [[4 [4 (AMINOIMINOMETHYL)PHENYL] 2 THIAZOLYL](1 CARBOXYMETHYL 4 PIPERIDINYL)AMINO]PROPIONIC ACID; 3 [[4 [4 [AMINO(ETHOXYCARBONYLIMINO)METHYL]PHENYL] 2 THIAZOLYL](1 ETHOXYCARBONYLMETHYL 4 PIPERIDINYL)AMINO]PROPIONIC ACID ETHYL ESTER; 4 [[3 [4 [IMINO[(METHOXYCARBONYL)AMINO]METHYL]PHENYL] 2 OXO 5 OXAZOLIDINYL]METHYL] 1 PIPERAZINEACETIC ACID ETHYL ESTER; ABCIXIMAB; AMIDINE; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 7A; CARBAMIC ACID DERIVATIVE; CARBOXYL GROUP; CT 50728; CT 51464; EMD 76334; EMD 94065; EPTIFIBATIDE; ESTER DERIVATIVE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; FRADAFIBAN; LEFRADAFIBAN; OXADIAZOLE DERIVATIVE; OXAZOLIDINONE DERIVATIVE; PRODRUG; SIBRAFIBAN; THROMBIN; THROMBIN INHIBITOR; TIROFIBAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; ENZYME; FIBRINOLYTIC AGENT;

ANTICOAGULATION; BINDING AFFINITY; BLEEDING; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; ENZYME SPECIFICITY; FOOD DRUG INTERACTION; HUMAN; ISCHEMIC HEART DISEASE; NONHUMAN; PHARMACEUTICAL ENGINEERING; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROCESS OPTIMIZATION; REVIEW; STRUCTURE ACTIVITY RELATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOEMBOLISM; THROMBOSIS; ANIMAL; BLOOD CLOTTING; DRUG ANTAGONISM; METABOLISM; PHYSIOLOGY;

ANIMALS; BLOOD COAGULATION; ENZYMES; FACTOR VIIA; FACTOR XA; FIBRINOLYTIC AGENTS; HUMANS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PRODRUGS; THROMBIN; THROMBOEMBOLISM;

EID: 33644853189     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206775193172     Document Type: Review

References (103)

1. Gresele P, Agnelli, G. Novel approaches to the treatment of thrombosis. Trends Pharmacol Sci 2002; 23: 25-32.
2. George JN. Platelets. Lancet 2000; 355: 1531-9.
3. Hirsh J, Weitz JI. Thrombosis and anticoagulation. Semin Hematol 1999; 36: 118-32.
4. Davie EW, Fujikawa K, Kisiel W. The coagulation cascade: initiation, maintenance, and regulation. Biochemistry 1991; 30: 10363-70.
5. Dahlbäck B. Blood coagulation. Lancet 2000; 355: 1627-32.
6. Esmon CT. Regulation of blood coagulation. Bioch Biophy Acta 2000; 1477, 349-60.
7. Coburn CA. Small-molecule direct thrombin inhibitors: 1997-2000. Exp Opin Ther Patents 2001; 11: 721-38.
8. Ripka WC. New thrombin inhibitors in cardiovascular disease. Curr Opin Chem Biol 1997; 1: 242-53.
9. Renwinkel JBM, Adang AEP. Strategies and progress towards the ideal orally active thrombin inhibitor. Curr Pharm Design 1999; 5: 1043-75.
10. Vacca J P. New advances in the discovery of thrombin and factor Xa inhibitors. Curr Opin Chem Biol 2000; 4: 394-400.
11. Rai R, Sprengeler PA, Elrod KC, Young WB. Perspectives on factor Xa Inhibition. Curr med Chem 2001; 8: 101-19.
12. Zablocki JA, Rao SN, Baron DA, Flynn DL, Nicholson NS, Feigen LP. Fibrinogen receptor antagonists. Curr Pharm Des 1995: 1: 533-58.
13. Ojima I, Chakravarty S, Dong Q. Antithrombotic Agents: From RGD to Peptide Mimetics. Bioorg Med Chem 1995; 3: 337-60.
14. Eldred CD, Judkins BD. In: King FD, Oxford AW Eds, Progress in Medical Chemistry. Amsterdam, Elsevier Science. 1999; 36: 29-90.
15. Hirsh J, Weitz JI. New antitrombotic agents. Lancet 1999; 353: 1431-6.
16. Hush J. Current anticoagulant therapy-unmet clinical needs. Thromb Res 2003; 109: S1-S8.
17. Raghavan SAV, Dikshit M. Recent advances in the status and targets of antithrombotic agents. Drugs of the future 2002; 7: 669-83.
18. Ruef J, Katus HA. New antithrombotic drugs on the horizon. Expert Opin Investig drugs 2003; 12: 781-97.
19. Balant L P. In: Abraham DJ Ed, Burger's Medicinal Chemistry and Drug Discovery, Volume 2, Drug discovery and Drug development. New York, John Wiley & Sons, Inc. 2003; 499-532.
20. Barrett AJ, Rawlings ND. Families and clans of serine peptidases. Arch Biochem Biophys 1995; 318: 247-50.
21. Bõhm H J, Klebe G, Kubinyi H. In Wirkstoffdesign. Heidelberg, Spektrum Akademisher Verlag. 1996, 469-85.
22. Rawlings ND, Barrett AJ. Families of serine peptidases. Methods Enzymolog 1994; 244: 19-61.
23. Leung D, Abbenante G, Fairle DP. Protease inhibitors: Current status and future prospects. J Med Chem 2000; 43: 307-41.
24. Bode W, Mayr I, Baumann U, Huber R, Stone S R, Hofsteenge J. The refined 1.9 A crystal structure of human alpha thrombin: interaction with D-Phe-Pro-Arg chloromethylketone and significance of the Tyr-Pro-Trp insertion segment. EMBO J 1989; 8: 3467-75.
25. Padmanabhan K, Padmanabhan KP Tulinsky A, Park C, Bode W, Huber R, et al. Structure of human des (1-45) factor Xa at 2.2 Å resolution. J Mol Biol 1993; 232: 947-66.
26. Brandstetter H, Kühne A, Bode W, Huber R, von der Saal W, Wirthensohn K, et al. X-ray structure of active site-inhibited clotting factor Xa. J Biol Chem 1996; 271: 29988-92.
27. The figure was produced using the program VMD 1.8 for Microsoft Windows 2000/XP. Data are from the Protein Data Bank-1ABI for the thrombin, 1FAX for the factor Xa and 1CVW for the factor VIIa.
28. Taparelli C, Metternich R, Ehrhardt C, Cook NS. Synthetic low-molecular weight thrombin inhibitors: molecular design and pharmacological profile. Trends Pharmacol Sci 1993; 14: 366-76.
29. Feng DM, Gardell SJ, Lewis SD, Bock MG, Chen ZG, Freidinger RM, et al. Discovery of a novel, selective, and orally bioavailable class of thrombin inhibitors incorporating aminopyridyl moieties at the P1 position. J Med Chem 1997; 40: 3726-33.
30. Lumma WC, Witherup KM, Tucker TJ, Brady SF, Sisko JT, NaylorOlsen AM, et al. Design of novel, noncovalent inhibitors of thrombin with nonbasic P-1 substructures: rapid structure- activity studies by solid-phase synthesis. J Med Chem 1998; 41: 1011-3.
31. Tucker TJ, Isaacs RCS. In: Advances in Amino Acid Mimetics and Peptidomimetics. New York, JAI Press Inc. 1999; 53-87.
32. Wiley MR, Weir LC, Briggs SI, Chirgadze NY, Clawson D, Gifford-Moore DS, et al. The design of potent, selective, non-covalent, peptide thrombin inhibitors utilizing imidazole as a S1 binding element. Bioorg Med Chem Lett 1999; 9: 2767-72.
33. Rewinkel JBM, Lucas H, van Galen PJM, Noach ABJ, van Dinther TG, Rood AMM, et al. 1-aminoisoquinoline as benzamidine isoster in the design and synthesis of orally active thrombin inhibitors. Bioorg Med Chem Lett 1999; 9: 685-90.
34. Peterlin-Mašič L, Mlinšek G, Šolmajer T, Trampuš-Bakija A, Stegnar M, Kikelj D. Novel thrombin inhibitors incorporating non-basic partially saturated heterobicyclic P1-arginine mimetics. Bioorg Med Chem Lett 2003; 13: 789-94.
35. Peterlin-Mašič L, Kranjc A, Marinko P, Mlinšek G, Šolmajer T, Stegnar M, et al Selective 3-Amino-2-pyridinone acetamide thrombin inhibitors incorporating weakly basic partially saturated heterobicyclic P1-Arginine mimetics. Bioorg Med Chem Lett 2003; 13: 3171-9.
36. Caulkett P W R, James R, Pearson S E, Slater A, Walker R P. WO 09957113.
37. Choi-Sledecky Y M, Becker m R, Green D M, Davis R, Ewing W R, Mason H J, et al Aminoisoquinolines: Design and Synthesis of an Orally Active Benzamidine Isostere for the Inhibition of Factor Xa. Bioorg Med Chem Lett 1999; 9: 2539-44.
38. Kucznier R, Grams F, Leinert H, von der Saal W Stegmeier K. EP 0937711.
39. 2-Aroylanthranilamide Inhibitors of Human Factor Xa. J Med Chem 2000; 43: 873-82.
40. Pruitt JR, Pinto DJ, Galemmo RA Jr, Alexander RS, Rossi KA, Wells BL, et al. Discovery of 1-(2-aminomethylphenyl)-3-trifluoromethyl-N-[3-fluoro- 2′-(aminosulfonyl)1,1′-biphenyl)]-4yl]-1H-pyrazole-5- carboxyamide (DPC602), a potent, selective, and orally bioavailable factor Xa inhibitor. J Med Chem 2003; 46:5298-315.
41. Quan ML, Ellis CD, He MY, Liauw AY, Woerner F J, Alexander R S, et al. Nonbenzamidine tetrazole derivatives as factor Xa inhibitors. Bioorg Med Chem Lett 2003; 13: 369-73.
42. Gould WR, Leadley RI. Recent advances in the discovery and development of direct coagulation factor Xa inhibitors. Curr Pharm Design 2003; 9: 2337-47.
43. Golino P. The inhibitors of the tissue factor:factor VII pathway. Thromb Res 2002;106:V257-65.
44. South MS, Case BL, Wood RS, Jones DE, Hayes MJ, Girard TJ, et al. Structure-based drug design of pyrazinone antithrombotics as selective inhibitors of the tissue factor VIIa complex. Bioorg Med Chem Lett 2003; 13: 2319-25.
45. Parlow JJ, Case BL, Dice TA, Fenton RL, Hayes MJ, Jones DE, et al. Design, parallel synthesis, and crystal structures of pyrazinone antithrombotics as selective inhibitors of the tissue factor VIIa complex. J Med Chem 2003; 46: 4050-62.
46. Suleymanov OD, Szalony JA, Salyers AK, Lachance RM, Parlow JJ, South MS, et al. Pharmacological interruption of acute thrombus formation with minimal hemorrhagic complications by a small molecule tissue factor/ factor VIIa inhibitor: Comparison to factor Xa and thrombin inhibition in a nonhuman primate thrombosis model. J Pharmacol Exp Ther 2003; 306: 1115-21.
47. Coller BS. Blockade of platelet GPIIb/IIIa receptors as an anti-thrombotic strategy. Circulation 1995; 92: 2373-80.
48. Fullard JF. The role of the platelet glycoprotein IIb/IIIa in thrombosis and haemostasis. Curr Pharm Des 2004; 10: 1567-1576.
49. Scarborough RM, Gretler DD. Platelet Glycoprotein IIb-IIIa Antagonists as Prototypical Integrin Blockers: Novel Parenteral and Potential Oral Antithrombotic Agents. J Med Chem 2000; 43: 3453-73.
50. Egbertson MS, Chang CT-C, Duggan ME, Gould RJ, Halczenko W, Hartman GD, Non-Peptide Fibrinogen Receptor Antagonists. 2. Optimization of Tyrosine Template as a Mimic for Arg-Gly-Asp. J Med Chem 1994; 37: 2537-51.
51. Bennett JS. Novel platelet inhibitors. Annu Rev Med 2001; 52; 161-84.
52. Curtin R. Intravenous glycoprotein IIb/IIIa antagonists: their benefits, problems and future developments. Curr Pharm Des 2004; 10: 1577-85.
53. Cox D. Oral GPIIb/IIIa antagonists: what went wrong? Curr Pharm Des 2004; 10: 1587-96.
54. Scarborough RM, Kleiman NS, Phillips DR. Platelet Glycoprotein IIb/IIIa Antagonists: What Are the Relevant Issues Concerning Their Pharmacology and Clinical Use? Circulation 1999; 100: 437-44.
55. Peter K, Schwarz M, Nordt T, Bode C. Intrinsic Activating Properties of GPIIb/IIIa Blockers Thromb Res 2001, 103, S21-7.
56. Beaumont K, Webster R, Gardner I, Dack, K. Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: Challenges to the discovery scientist. Curr Drug Metab 2003; 4: 461-85.
57. Albert A, Goldacre R, Philips J. The strength of heterocyclic bases. J Chem Soc 1948; 2240-49.
58. Oszczapowicz, J. In: Patai S, Rappoport Z Eds, The Chemistry of Amidines and Imidates. London, John Wiley & Sons Ltd 1991; vol.2: pp. 623.
59. Hauptmann J, Paintz M, Kaiser B, Richter M. Reduction of benzamidoxime derivative to the corresponding benzamidine in vitro and in vivo. Pharmazie 1988; 43: 559-60.
60. Clement B, Schmitt S, Zimmermann M. Enzymatic reduction of benzamidoxime to benzamidine. Arch Pharm 1988: 321, 955-56.
61. Clement B. Reduction of N-hydroxylated compounds (amidoximes (N-hydroxy-amidines) as pro-drugs of amidines. Drug Metab Rev 2002; 34: 565-79.
62. Alexander J, Cargill R, Michelson S R, Schwam H. (Acyloxy)alkyl carbamates as novel bioreversible prodrugs for amines: increased permeation through biological membranes. J Med Chem 1988; 31: 318-22.
63. Shahrokh Z, Lee E, Olivero AG, Matamoros RA, Robarge KD, Lee A, et al. Stability of alkoxycarbonylamidine prodrugs. Pharm Res 1998; 3: 434-41.
64. Kitamura S, Fukushi H, Miyawaki T, Kawamura M, Terashita Z, Naka T. Orally active GPIIb/IIIa antagonists: Synthesis and biological activities of masked amidines as prodrugs of 2-[(3S)-4-[(2S)-2- (4-amidinobenzoylamino)-3-(4-methoxyphenyl)propanoyl]-3- (2-methoxy-2-oxoethyl)-2-oxopiperazinyl]acetic acid. Chem Pharm Bull 2001; 49: 268-77.
65. Wang W, Borchardt RT, Wang B. Orally Active Peptidomimetic RGD Analogs that are Glycoprotein IIb/IIIa Antagonists. Curr Med Chem 2000; 7: 437-53.
66. Weller T, Alig L, Beresini M, Blackburn B, Buntig S, Hadváry P, et al. Orally active fibrinogen receptor antagonists. 2. Amidoximes as prodrugs of amidines. J Med Chem 1996; 39: 3139-47.
67. Wittke B, Mackie IJ, Machin SJ, Timm U, Zell M, Goggin T. Pharmacokinetics and pharmacodynamics of Ro-3888 after single ascending oral doses of sibrafiban, an oral platelet aggregation inhibitor, in healthy male volunteers. Br J Clin Pharmacol 1999; 47: 521-30.
68. SYMPHONY Investigators. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomized trial. Lancet 2000; 355: 337-45.
69. Mehrotra MM, Heath JA, Smyth MS, Pandey A, Rose JW, Seroogy JM, et al. Discovery of novel 2,8-diazaspiro[4.5]decanes as orally active glycoprotein IIb-IIIa antagonists. J Med Chem 2004; 47: 2037-61.
70. Müller TH, Weisenberger H, Brickl R, Narjes H, Himmelsbach F, Krause J. Profound and sustained inhibition of platelet aggregation by fradafiban, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, and its orally active prodrug, lefradafiban, in men. Circulation 1997; 96: 1130-38.
71. Akkerhius KM, Neuhaus KL, Wilcox RG, Vahanian A, Boland JL, Hoffmann J, et al. Safety and preliminary efficacy of one month glycoprotein IIb/ IIIa inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation. A phase II study. Eur Heart J 2000; 21: 2042-55.
72. Gante J, Juraszyk H, Raddatz P, Wurziger H, Bernotat-Danielowski S, Melzer G, et al. New antithrombotic RGD-mimetics with high bioavailability. Bioorg Med Chem Lett 1996; 6: 2425-30.
73. Badorc A, Bordes MF, De Cointet P, Savi P, Bernat A, Lalé A, et al. New orally active non-peptide fibrinogen receptor (GPIIb/IIIa) antagonists: identification of ethyl 3-[N-[4-[4-[amino[(ethoxycarbonyl)imino]methyl]phenyl]- 1,3-thiazol-2-yl]-N-[1-(ethoxycarbonyl)methyl]piperid-4- yl]amino]propionate (SR 121787) as a potent and long-acting antithrombotic agent. J Med Chem 1997; 40: 3393-401.
74. Prous Science Daily Essentials, December 30, 2003; AstraZeneca News Release.
75. Gustafsson D, Bylund R, Antonsson T, Nilsson I, Nyström JE, Eriksson U, et al. A new oral anticoagulant: The 50-year challenge. Nat Rev Drug Disc 2004; 3: 649-59.
76. Weitz JI, Crowther M. Direct thrombin inhibitors. Thromb Res 2002; 106: V275-84.
77. Sarich TC, Wolzt M, Eriksson UG, Mattsson C, Schmidt A, Elg S, et al. Effects of ximelagatran, an oral direct thrombin inhibitor, rhirudin and enoxaparin on thrombin generation and platelet activation in healthy male subject. J Am Coll Cardiol 2003; 41: 557-64.
78. Gustafsson D. Nyström JE, Carlsson S, Bredberg U, Eriksson U, Gyzander E, et al. The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb Res 2001; 101: 171-81.
79. Gustafsson D, Elg M. The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review. Thromb Res 2003; 109: S8-15.
80. Gustafsson D. Oral direct thrombin inhibitors in clinical development. J Intern Med 2003; 254: 322-34.
81. Larsson M, Ahnoff M, Abrahamsson A, Logren U, Fakt C, Öhrman I, Persson BA. Determination of ximelagatran, an oral direct thrombin inhibitor, its active metabolite melagatran, and the intermediate metabolites, in biological samples by liquid chromatography-mass spectrometry. J Chromatogr B 2003; 783: 335-47.
82. Eriksson UG, Bredberg U, Hoffman KJ, Thuresson A, Gabrielsson M, Eriksson H, et al. Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans. Drug Metabol Dispos 2003; 31: 294-305.
83. Johansson LC, Frison L, Logren U, Fager G, Gustafsson D, Eriksson UG. Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. Clin Pharmacokinet 2003; 42: 381-92.
84. Nystroem J-E, Inghardt T. WO 0042059.
85. Inghardt T, Svensson A. WO 0214270.
86. Inghardt T, Johansson A. Svensson A. WO 0244145.
87. Lee K, Lee SH, Park HD, Park S-K, Hwang S, Kim A, et al. WO 2004002985.
88. Zega A, Mlinšek G, Šolmajer T, Trampuš-Bakija A, Stegnar M, Urleb U. Thrombin inhibitors built on azaphenylalanine scaffold. Bioorg Med Chem Lett 2004; 14 1563-7.
89. Hauel NH, Nar H, Priepke H, Ries U, Stassen JM, Wienen W. Structure-based design of novel potent nonpeptide thrombin inhibitors. J Med Chem 2002; 45: 1757-66.
90. Mungall D. BIBR-1048 Boehringer Ingelheim. Curr Opin Investig Drugs 2002; 3: 905-07.
91. Song Y, Clizbe L, Bhakta C, Teng W, Wong P, Huang B, et al. Design and synthesis of factor Xa inhibitors and their prodrugs. Bioorg Med Chem Lett 2003, 13: 297-300.
92. Song Y, Zhu BY, Scarborough RM, WO 0047553.
93. Nagahara T, Komoriya S, Nagata T. JP 2002105041.
94. Pinto DJP, Orwat MJ, Wang S, Fevig JM, Quan ML, Amparo E, et al. Discovery of 1-(3-(aminomethyl)phenyl)-N-[3-fluoro-2-methylsulfonyl)- (1,1′-biphenyl)-4-yl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem 2001; 44: 566-78.
95. Sanderson PE, Lyle TA, Cutrona KJ, Dyer DL, Dorsey BD, McDonough CM, et al. Efficacious, orally bioavailable thrombin inhibitors based on 3-aminopyridinone or 3-aminopyrazinone acetamide peptidomimetic template. J Med Chem 1998; 41: 4466-74.
96. Newman W, Case B, Jones DE, Parlow JJ, Toth MV, Trujillo J, et al. WO 03028729.
97. Ackermann J, Alig L, Chucholowski A, Groebkc K, Hilpert K, Kuehne H, et al. WO 0035858.
98. Alig L, Groebke K, Hilpert K, Kuehne H, Obst U, Wessel H P. WO 0190051.
99. Kranjc A, Kikelj A. Dual inhibitors of the blood coagulation cascade enzymes. Curr Med Chem 2004; in press.
100. Ries UJ. Heterocyclic coagulation inhibitors: Design, syntheses and biological properties of orally avtive, dual direct thrombin and factor Xa inhibitors. The 226th ACS National Meeting, New York, NY. 2003, Book of Abstracts, MEDI-033.
101. Gould WR, Leadley RJ. Recent advances in the discovery and development of direct coagulation factor Xa inhibitors. Curr Pharm Design 2003; 9(28): 2337-47.
102. Gruber A, Hanson SR. Potential new targets for antithrombotic therapy. Curr Pharm Design 2003; 9(28): 2367-74.
103. Salzet M. Leech thrombin inhibitors. Curr Pharm Design 2002; 8(7): 493-503.